Phase 4 N=136 Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy
Colon Cancer
Primary: Boston Prep Scale — 7.0; 7.2 units on a scale — p=.45
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=434 A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation
Heart Transplantation
Primary: Number of Participants Who Developed Acute Rejection Episode Within 6 Months Post-Transplant — 77; 104 participants — p=0.007
Phase 4 N=491 Research Evaluating the Value of Augmenting Medication With Psychotherapy
Depression · Depressive Disorder
Primary: Remission — 38.5; 31.0; 39.5 percentage of participants
Phase 4 N=195 Comparing Subsartorial Saphenous Nerve Blocks With and Without Dexamethasone for Anterior Cruciate Ligament Reconstruction
Anterior Cruciate Ligament Reconstruction · Regional Anesthesia, Saphenous Nerve Block
Primary: Patient-perceived Duration of Analgesia — 33; 41; 46.5 hours
Phase 4 N=57 A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval
Cancer
Primary: Treatment Difference in Duration of Cardiac Ventricular Depolarization and Repolarization Interval (QT) in Fridericia-corrected QT Interval (QTcF) Values Between Placebo…
Phase 4 N=57 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin
Hepatitis C, Chronic
Primary: Number of Pegasys and Ribavirin Therapy Completers — 3; 23; 2; 23 Participants
Phase 4 N=65 A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)
Adult Refractory Complex Partial Seizures
Primary: Mean Change From Reference Value in Field Width as Measured by 30-2 SITA Fast in Field Sensitivity (Mean Deviation - MD in dB) — -0.28; -0.24; -0.14; -0.13 dB
Phase 4 N=42 A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720
Multiple Sclerosis · Relapsing-Remitting
Primary: Mean Patient-Reported Treatment Satisfaction Questionnaire for Medication Scores (TSQM-9) — 32.0; 44.7 Scores on a scale
Phase 4 N=62 A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall
Attention Deficit Hyperactivity Disorder
Primary: Medication Event Monitoring System (MEMS®) Dosage Adherence — 42.7; 66.2 percentage of participants adherent
Phase 4 N=189 A Study of Two-Weekly Intravenous Mircera for the Treatment of Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy.
Anemia
Primary: Mean Change in Hemoglobin Concentration From Baseline to Week 16 of the Treatment Period — 2.11 gram/deciliter (g/dL) — p=<0.0001
Phase 4 N=8 NMDA Antagonists in Bipolar Depression
Bipolar Disorder
Primary: Hamilton Depression Rating Scale (HAM-D) — 9.5 units on a scale (final score) — p=<0.001
Phase 4 N=120 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns
Multiple Sclerosis · Urinary Bladder Diseases
Primary: Change From Baseline in the King's Health Questionnaire (KHQ) Domain Scores — 39.7; 2.5; 60.7; 1.2 Scores on a Scale
Phase 4 N=280 A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine
Migraine Disorders
Primary: Percentage of Patients With Adverse Events — 24.37 Percentage of Patients
Phase 4 N=30 Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults
Major Depressive Disorder · Back Pain · Aged
Primary: Change in Montgomery Asberg Depression Rating Scale(MADRS) Score From Baseline and 12 Weeks — -11.7 units on a scale
Phase 4 N=28 A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris
Acne Vulgaris
Primary: Mean Change From Baseline in Total Lesion Count — -26.9 Lesions counted